Transgene and NEC Ink License for Cancer Vaccine
Transgene S.A., a biotech company focused on virus-based immunotherapies, and NEC Bio B.V., a subsidiary of NEC Corporation, signed a license agreement on April 2, 2026, to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine for adjuvant treatment of resected HPV-negative head and neck cancer, according to GlobeNewswire PE. Under the agreement, Transgene gains access to NEC’s AI-based neoantigen prediction platform for further development of TG4050, which uses an MVA viral vector to target patient-specific tumor mutations.
Details of the Agreement
TG4050 is designed to stimulate the immune system against neoantigens identified via NEC’s proprietary platform, which employs machine learning to select immunogenic mutations for head and neck cancer patients post-surgery and adjuvant therapy. NEC retains full ownership of its AI platform and will support Transgene’s clinical activities, as outlined in the agreement. The deal enables Transgene to pursue further clinical development and potential commercialization of TG4050 while conferring rights for partnering.
Financial Aspects
NEC will receive a technology access fee of €2.5 million in Transgene shares upon signing and an additional €2.5 million in cash paid in tranches through early 2028, according to GlobeNewswire PE. Further payments include milestone-based amounts, with part in Transgene shares, development milestone payments, and a double-digit share of any profits or licensing revenues. This structure positions NEC as a shareholder in Transgene.
Company Perspectives
Dr. Alessandro Riva, Chairman and CEO of Transgene, stated that the agreement builds on their collaboration and strengthens TG4050’s development using data from ongoing Phase 2 trials, as per the source material. NEC’s role includes providing ongoing support for clinical activities, reflecting their confidence in the program, according to GlobeNewswire PE. As widely-known context, biotech licensing deals like this often facilitate innovation in cancer treatments by combining AI and immunotherapy expertise.
